Skip to content
My WebMD Sign In, Sign Up

Asthma Health Center

Font Size

Omalizumab for Asthma - Topic Overview

Omalizumab (Xolair) is a medicine approved by the U.S. Food and Drug Administration (FDA) for use in people age 12 and older who have moderate or severe persistent asthma. It should be used only after first-line treatments (such as corticosteroids and long-acting beta2-agonists) have failed. Omalizumab is much more expensive than any of the conventional treatments for asthma. And its role in asthma treatment is not clear.

Omalizumab works by blocking immunoglobulin E (IgE) from attaching to allergens. When IgE attaches to an allergen, it sets off a process that eventually leads to the symptoms of an allergic reaction.

Recommended Related to Asthma

Asthma in Children at School

Being the parent of a child with asthma can be frightening. You may feel especially helpless when your son or daughter goes off to school. At home, you can control the environment to reduce the impact of asthma triggers and you know what to do in an emergency. But when your child is at school, you may feel as though your child's well-being is out of your control. Even so, there's a lot parents can do to help control asthma in children at school. It's key that you work closely with the school's staff...

Read the Asthma in Children at School article > >

Initial studies show that omalizumab reduces asthma episodes, improves peak expiratory flow (PEF), reduces the need for other medicines, and reduces emergency room visits and hospitalization.1 But it has been studied only in people with positive skin tests to indoor allergens such as dust mites, animal dander, cockroaches, and molds.

Omalizumab is injected, and the dose is determined by a person's body weight and IgE level.

Omalizumab appears to be effective in people who:1

  • Are age 12 and older.
  • Have moderate or severe persistent asthma.
  • Have asthma that can be improved.
  • Have had a positive skin or blood test for a specific allergen.
  • Have blood levels of immunoglobulin E between 30 and 700 IU per milliliter.

Omalizumab can be considered in people who meet the above criteria and whose asthma is not well controlled after using inhaled corticosteroids and long-acting beta2-agonists or leukotriene pathway modifiers for 3 months. People who use oral or injected (systemic) corticosteroids or who require high doses of inhaled corticosteroids for daily control can also consider using omalizumab.

Severe allergic reactions, including anaphylaxis, are possible when taking omalizumab, but this is rare. So people who get omalizumab are watched for 2 hours after they receive their first 2 doses. They should also carry epinephrine (EpiPen) in case they have an allergic reaction after omalizumab treatment.

1

WebMD Medical Reference from Healthwise

Last Updated: February 22, 2013
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

When Is Your Asthma Worse?

When Is Your Asthma Worse?

Take the WebMD Asthma assessment to get Personalized Action Plan

Start Now

Today on WebMD

Distressed woman
Slideshow
Woman holding an asthma inhaler
Article
 
Get Personalized Asthma Advice
Health Check
asthma overview
Slideshow
 
Los Angeles skyline in smog
Slideshow
man in a field with allergies
Slideshow
 
Woman holding inhaler
VIDEO
Slideshow Allergy Myths and Facts
Slideshow
 
Man outdoors coughing
Article
Lung and bronchial tube graphic
Article
 
10 Worst Asthma Cities
Slideshow
runner
Article